New York, May 17, 2026, 15:03 (EDT)
- Pfizer (PFE) closed Friday at $25.33, down 1.63%. Shares slipped around 1.4% from the May 8 close of $25.68.
- S&P 500 slid 1.24% Friday, but still locked in a seventh straight weekly gain.
- Pfizer beat estimates as attention held on its cancer, obesity drugs and dividend. The company kept its 2026 forecast unchanged.
Pfizer Inc. (PFE) is starting the week stuck after shares fell Friday. Investors have yet to see if a better quarter is enough for ongoing growth. With U.S. markets shut over the weekend, PFE last traded at $25.33 on Friday.
Stocks slid Friday as macro worries returned. The S&P 500, Dow, and Nasdaq all lost more than 1%. Treasury yields moved higher again, adding to the pressure as bonds drew more interest and stock valuations tightened.
Pfizer (PFE) opened the week strong, with shares up from Monday through Wednesday, but the stock gave back those gains in the last two sessions. By Friday’s close, Pfizer was down compared to May 8. The S&P 500 edged out a small weekly gain.
Pfizer (PFE) first-quarter sales came in at $14.451 billion, a 5% gain year on year. Adjusted diluted EPS was 75 cents. That excludes some charges. The company stuck with its 2026 forecast: revenue of $59.5 billion to $62.5 billion and adjusted EPS between $2.80 and $3.00. Shares are lagging the numbers.
Pfizer execs are urging investors to be patient. CEO Albert Bourla told investors Pfizer is “off to a strong start” for 2026 and pointed to oncology and obesity as areas where the company is “positioned to lead.” CFO David Denton said Pfizer saw 22% operational revenue growth, excluding currency effects, in products that are already on the market or were acquired. BioSpace
Pfizer is moving into what CFO David Denton called “a new phase,” speaking to investors about new medicines and the pipeline as growth engines for later this decade. Denton said this is where the company wants shareholder support. The Motley Fool
Wall Street is quiet on the news. Trung Huynh at RBC Capital called Pfizer “a catalyst story, not an earnings story,” using “catalyst” to mean a potential driver for the shares. Chris Schott at J.P. Morgan said investors need to see additional clinical data and reduced pipeline risk before sentiment changes. Reuters
Eli Lilly holds the top spot right now. The company’s obesity and diabetes unit has set a new standard for GLP-1 drugs, which target diabetes and weight loss. Pfizer, after buying Metsera for $10 billion, doesn’t expect to launch its first obesity drug before 2028, and that’s only if the trials work out. Pfizer’s Chief U.S. Commercial Officer Aamir Malik said the company brings “unique capabilities” in the obesity space. CEO Albert Bourla told investors he was surprised by “how big the international market is.” Reuters
Pfizer is still getting support from established drugs. Eliquis, co-sold with Bristol Myers Squibb, pulled in $2.17 billion for Q1, Reuters reported. Some of the fall from its COVID products was offset by new additions like Padcev and Nurtec. Revenue from the Comirnaty vaccine fell 59% year over year.
Pfizer paid out $2.4 billion in dividends to shareholders in the first quarter, or 43 cents a share. No share repurchases in 2026 so far. Its guidance for the year does not include stock buybacks.
Nvidia is set to report Wednesday, and Walmart follows on Thursday, bringing more attention to AI and consumer trends. But the main story this week could be the S&P 500 as much as Pfizer. With the index near all-time highs, even a major health headline can fade into the background while market shifts get the focus.
Title: Risks pulling on Pfizer shares as yields, pipeline news sway trade Oil-related inflation can keep bond yields up and weigh on stocks like Pfizer if buyers stay away. If the company’s obesity and cancer studies fail to ease those worries, its first-quarter beat might not last. Still, if yields fall or pipeline updates get a good reaction, Friday’s drop could look more like a macro move than something tied to Pfizer itself.
Pfizer will test where it stands with investors on Monday, as traders look past the company’s COVID run. Some may see Pfizer as a reliable dividend play hurt by market pressure, but the stock still needs to win back confidence.
